Agentix Corp. (AGTX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
32932 PACIFIC COAST HIGHWAY DANA POINT, CA 92629 |
| State of Incorp. | NV |
| Fiscal Year End | March 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 MRQ | 3/31/2024 | 3/31/2023 | 8/31/2021 | 8/31/2020 | 8/31/2019 | 8/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 12 | 2 | 243 | 0 | 2 | ||||
| Cash and cash equivalent | 12 | 2 | 243 | 0 | 2 | ||||
| Inventory, net of allowances, customer advances and progress billings | 49 | ||||||||
| Inventory | 49 | ||||||||
| Prepaid expense | |||||||||
| Other undisclosed current assets | 106 | 249 | 50 | ||||||
| Total current assets: | 106 | 261 | 51 | 293 | 0 | 2 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 0 | ||||||||
| Total noncurrent assets: | 0 | ||||||||
| TOTAL ASSETS: | 106 | 261 | 51 | 293 | 0 | 2 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 985 | 1,066 | 121 | 41 | 11 | 2 | |||
| Accounts payable | 962 | 1,057 | 121 | 41 | 7 | ||||
| Accrued liabilities | 24 | 9 | 0 | 0 | 4 | 2 | |||
| Debt | (25) | ||||||||
| Due to related parties | ✕ | ✕ | 1,394 | 486 | 28 | 5 | 8 | ||
| Other undisclosed current liabilities | 1,681 | 50 | 50 | ||||||
| Total current liabilities: | 2,667 | 2,511 | 607 | 69 | 41 | 10 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 85 | 46 | |||||||
| Long-term debt, excluding current maturities | 85 | 46 | |||||||
| Total noncurrent liabilities: | 85 | 46 | |||||||
| Total liabilities: | 2,667 | 2,511 | 607 | 69 | 126 | 55 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (2,560) | (2,249) | (556) | 223 | (126) | (53) | |||
| Common stock | 40 | 40 | 35 | 34 | 0 | 21 | |||
| Common stock, value, subscriptions | 54 | ||||||||
| Additional paid in capital | 3,288 | 3,026 | 934 | 553 | 43,905 | 43,824 | |||
| Accumulated other comprehensive income | 12 | ||||||||
| Accumulated deficit | (5,954) | (5,369) | (1,704) | (364) | (44,031) | (43,898) | |||
| Other undisclosed equity, attributable to parent | 54 | 1 | 180 | ||||||
| Total equity: | (2,560) | (2,249) | (556) | 223 | (126) | (53) | |||
| TOTAL LIABILITIES AND EQUITY: | 106 | 261 | 51 | 293 | 0 | 2 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 TTM | 3/31/2024 | 3/31/2023 | 8/31/2021 | 8/31/2020 | 8/31/2019 | 8/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 198 | 1 | ||||||
| Other income | 198 | |||||||
| Cost of revenue (Cost of Product and Service Sold) | (1) | |||||||
| Gross profit: | 198 | 1 | ||||||
| Operating expenses | (745) | (1,372) | (1,341) | (121) | (134) | |||
| Other operating income, net | 11 | |||||||
| Other undisclosed operating loss | (198) | (1) | (11) | |||||
| Operating loss: | (745) | (1,372) | (1,341) | (121) | (134) | |||
| Nonoperating income (expense) | (160) | 0 | (0) | 42,655 | ||||
| Gain, foreign currency transaction, before tax | 0 | |||||||
| Other nonoperating income (expense) | (160) | (0) | 42,655 | |||||
| Interest and debt expense | (21) | (2) | (11) | 42,630 | ||||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | ||||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (926) | (1,373) | (1,341) | (133) | 85,150 | |||
| Other undisclosed income from continuing operations before income taxes | 340 | 1 | ||||||
| Income (loss) from continuing operations: | (585) | (1,373) | (1,340) | (133) | 85,150 | |||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (1,340) | ✕ | (133) | 85,150 | |
| Other undisclosed net loss | ||||||||
| Net income (loss): | (585) | (1,373) | (1,340) | (133) | 85,150 | |||
| Other undisclosed net income (loss) attributable to parent | (1) | (127,939) | ||||||
| Net loss available to common stockholders, diluted: | (585) | (1,374) | (1,340) | (133) | (42,789) | |||
Comprehensive Income ($ in thousands)
| 12/31/2024 TTM | 3/31/2024 | 3/31/2023 | 8/31/2021 | 8/31/2020 | 8/31/2019 | 8/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (585) | (1,373) | (1,340) | (133) | 85,150 | |||
| Other comprehensive loss | (1,373) | |||||||
| Other undisclosed comprehensive loss | ||||||||
| Comprehensive income (loss): | (585) | (2,746) | (1,340) | (133) | 85,150 | |||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 12 | |||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (574) | (2,746) | (1,340) | (133) | 85,150 | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.